NorthRock Partners LLC Makes New $205,000 Investment in Becton, Dickinson and Company (NYSE:BDX)

NorthRock Partners LLC bought a new stake in shares of Becton, Dickinson and Company (NYSE:BDX) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 830 shares of the medical instruments supplier’s stock, valued at approximately $205,000.

A number of other institutional investors have also recently made changes to their positions in the stock. Ridgewood Investments LLC grew its holdings in shares of Becton, Dickinson and Company by 1.5% in the first quarter. Ridgewood Investments LLC now owns 2,956 shares of the medical instruments supplier’s stock valued at $731,000 after purchasing an additional 43 shares in the last quarter. Key Client Fiduciary Advisors LLC grew its stake in shares of Becton, Dickinson and Company by 2.6% in the 1st quarter. Key Client Fiduciary Advisors LLC now owns 1,715 shares of the medical instruments supplier’s stock worth $424,000 after buying an additional 43 shares in the last quarter. CWM LLC increased its holdings in shares of Becton, Dickinson and Company by 0.7% in the 4th quarter. CWM LLC now owns 6,303 shares of the medical instruments supplier’s stock worth $1,537,000 after buying an additional 46 shares during the last quarter. S.A. Mason LLC raised its position in shares of Becton, Dickinson and Company by 3.5% during the 4th quarter. S.A. Mason LLC now owns 1,420 shares of the medical instruments supplier’s stock valued at $346,000 after buying an additional 48 shares in the last quarter. Finally, Edge Capital Group LLC lifted its holdings in shares of Becton, Dickinson and Company by 3.1% in the 4th quarter. Edge Capital Group LLC now owns 1,573 shares of the medical instruments supplier’s stock valued at $384,000 after acquiring an additional 48 shares during the last quarter. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Up 0.6 %

Shares of BDX stock traded up $1.26 during trading hours on Tuesday, reaching $227.34. 48,266 shares of the company’s stock were exchanged, compared to its average volume of 1,429,820. The stock has a market cap of $65.70 billion, a PE ratio of 49.80, a PEG ratio of 2.01 and a beta of 0.42. The company has a current ratio of 1.41, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62. The stock’s fifty day moving average price is $232.71 and its two-hundred day moving average price is $236.72. Becton, Dickinson and Company has a 1 year low of $218.75 and a 1 year high of $287.32.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, May 2nd. The medical instruments supplier reported $3.17 earnings per share for the quarter, beating analysts’ consensus estimates of $2.97 by $0.20. Becton, Dickinson and Company had a net margin of 6.76% and a return on equity of 13.90%. The firm had revenue of $5.05 billion for the quarter, compared to analyst estimates of $5.04 billion. During the same period in the previous year, the company earned $2.86 earnings per share. The business’s quarterly revenue was up 4.6% compared to the same quarter last year. Research analysts predict that Becton, Dickinson and Company will post 13.04 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, June 28th. Investors of record on Monday, June 10th were issued a dividend of $0.95 per share. The ex-dividend date of this dividend was Monday, June 10th. This represents a $3.80 annualized dividend and a dividend yield of 1.67%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 83.70%.

Wall Street Analyst Weigh In

BDX has been the subject of several analyst reports. Barclays raised their price objective on Becton, Dickinson and Company from $305.00 to $312.00 and gave the company an “overweight” rating in a research note on Monday, May 6th. Citigroup dropped their price objective on shares of Becton, Dickinson and Company from $260.00 to $255.00 and set a “neutral” rating for the company in a research note on Wednesday, July 10th. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Monday. Evercore ISI cut their price target on shares of Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating on the stock in a report on Tuesday, July 2nd. Finally, The Goldman Sachs Group began coverage on Becton, Dickinson and Company in a research note on Thursday, May 30th. They set a “buy” rating and a $274.00 target price on the stock. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $280.14.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, SVP Thomas J. Spoerel sold 300 shares of the business’s stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $239.31, for a total value of $71,793.00. Following the completion of the transaction, the senior vice president now directly owns 1,976 shares of the company’s stock, valued at $472,876.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Becton, Dickinson and Company news, EVP Roland Goette sold 3,300 shares of the stock in a transaction that occurred on Wednesday, May 15th. The stock was sold at an average price of $236.73, for a total transaction of $781,209.00. Following the completion of the transaction, the executive vice president now owns 11,308 shares of the company’s stock, valued at $2,676,942.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Thomas J. Spoerel sold 300 shares of the firm’s stock in a transaction on Monday, June 10th. The shares were sold at an average price of $239.31, for a total value of $71,793.00. Following the completion of the transaction, the senior vice president now owns 1,976 shares in the company, valued at approximately $472,876.56. The disclosure for this sale can be found here. Insiders sold 8,615 shares of company stock worth $2,033,381 over the last three months. Company insiders own 0.31% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.